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Introduction: The importance of identifying non-small cell lung
cancer (NSCLC) histologic subtype has increased recently because
of the development of target-specific chemotherapeutic agents. This
systematic review was undertaken to examine the interobserver
variability for histology in differentiating between subtypes of
NSCLC, specifically the ability to differentiate squamous from
nonsquamous histology.
Methods: A systematic literature search was undertaken to identify
studies that evaluated the reproducibility of histologic diagnosis by
pathologists in their reporting of NSCLC subtypes. Studies were
screened using a priori defined eligibility criteria. The National
Health and Medical Research Council diagnostic levels of evidence
were applied and quality assessed using the Quality Assessment of
Diagnostic Accuracy Studies tool. Data were extracted and reana-
lyzed to permit comparison of agreement in nonsquamous and
squamous cell carcinoma by 2 2 tables. Percentage agreement and
kappa statistics were calculated for each included study.
Results: Out of 1480 articles identified through the literature search,
six were eligible for inclusion. The percentage agreement for all
subtypes of NSCLC in the included studies ranged from 67.1 to
89.6% (, 0.42–0.84). Based on the primary reanalysis of data
(reanalysis 1), agreement between pathologists in differentiating
nonsquamous and squamous histology ranged from 77.0 to 94.2%
(  0.48–0.88) indicating a moderate to high level of agreement.
Conclusion: The reasonably high agreement and kappa statistics for
the included studies suggest that pathologists can reproducibly
differentiate between nonsquamous and squamous NSCLC. This is
clinically important in guiding oncologist decision making in choos-
ing the most appropriate therapy for their patients.
Key Words: Systematic review, Histology, Non-small cell, Lung
cancer.
(J Thorac Oncol. 2011;6: 55–63)
Lung cancer is the most common cancer in the world.1There are approximately 1.2 million deaths due to lung
cancer every year.2 It is estimated that 80 to 85% of all lung
cancer cases are non-small cell lung cancer (NSCLC).3 Tra-
ditionally, surgical pathologists have taken great care to
distinguish small cell lung cancer (SCLC) from NSCLC
because of the vastly different natural histories and treatment
options but have placed less importance on further classifying
NSCLC into the major subtypes of adenocarcinoma, squa-
mous cell carcinoma, or large cell undifferentiated carci-
noma. The importance of identifying NSCLC histologic sub-
type has increased recently because of a shift in epidemiology
and an increasing number of target-specific chemotherapeutic
agents.4 The identification of prognostic and predictive fac-
tors may enable a more individualized treatment approach for
specific subsets of patients with NSCLC. Prognostic factors
are associated with outcomes independent of treatment,
whereas predictive factors are associated with, and predict,
the clinical effect size of a specific treatment.5 Some of the
clinical prognostic factors associated with survival in ad-
vanced or metastatic NSCLC are performance status, stage of
disease at the time of diagnosis, gender, weight loss, and
smoking history.6,7
Currently, according to the World Health Organization
(WHO) 2004 classification,8 pulmonary squamous cell carci-
noma is defined as “a malignant epithelial tumor showing
keratinisation and/or intercellular bridges that arises from
bronchial epithelium.” Adenocarcinoma is defined as a “ma-
lignant epithelial tumor with glandular differentiation or mu-
cin production, showing acinar, papillary, bronchioloalveolar
or solid with mucin growth patterns or a mixture of these
patterns.” Large cell carcinoma is defined by exclusion as “an
undifferentiated non-small cell carcinoma that lacks the cy-
tologic and architectural features of small cell carcinoma and
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glandular or squamous differentiation.” According to WHO
2004 classification “Specific diagnosis of large cell carci-
noma and variants can only be reliably achieved on surgical
material.”8 A mixed group, termed adenosquamous carci-
noma, is also recognized as a “carcinoma showing compo-
nents of both squamous cell carcinoma and adenocarcinoma
with each comprising at least 10% of the tumor.”9
Historically, these definitions have been of little signif-
icance because histologic subtype has not been demonstrated
to be predictive for treatment effect outcomes in NSCLC.
Nevertheless, recent data suggesting that specific chemother-
apeutic regimens are most active in nonsquamous NSCLC
have prompted a renewed interest in histology as a potential
predictive factor. A retrospective analysis of a trial compar-
ing second-line pemetrexed with docetaxel in NSCLC sug-
gested that a significant treatment-by-histology interaction
may exist with better efficacy in patients with nonsquamous
NSCLC compared with patients with squamous NSCLC
(hazard ratio [HR], 0.78; 95% confidence interval [CI]: 0.61–
1.0; HR, 1.56; 95% CI: 1.08–2.26, respectively).10 Subse-
quently, a prospective analysis of a phase III randomized trial
comparing first-line pemetrexed and cisplatin with gemcitab-
ine and cisplatin in NSCLC examined histologic subgroups of
NSCLC. Patients with nonsquamous NSCLC had a longer
overall survival time on cisplatin plus pemetrexed than on
cisplatin plus gemcitabine (HR, 0.84; 95% CI: 0.74–0.96;
p  0.011), whereas patients with squamous NSCLC had a
shorter overall survival time on cisplatin plus pemetrexed
than on cisplatin plus gemcitabine (HR, 1.23; 95% CI: 1.00–
1.51; p  0.050).11 A post hoc analysis of outcome by
histology in another key phase III trial (bevacizumab and
carboplatin taxol chemotherapy versus chemotherapy alone)
indicated the greatest benefit in the adenocarcinoma sub-
group.12 In the maintenance setting, a study of pemetrexed
noted a significant treatment-by-histology interaction with
both progression-free survival (p  0.036) and overall sur-
vival (p 0.033).13 The hypothesis behind the greater benefit
of pemetrexed in adenocarcinoma and large cell carcinoma
seems to lie with the observation that thymidilate synthetase
tumor levels (an enzyme target of pemetrexed) seem to be
higher in squamous cell carcinomas than in adenocarcinomas
and large cell carcinomas.14,15 Further research is warranted
to investigate whether biomarker status can help identify the
patients who will benefit from pemetrexed or other emerging
therapies.
The treatment-by-histology interaction effect has been
accepted by regulatory bodies in the United States, Europe,
and Canada; health technology assessment evidence-based
agencies in Europe (France, Italy, Switzerland, and Spain) and
the United Kingdom (National Institute for Health and Clinical
Excellence); and independent clinical guideline groups (Euro-
pean Society for Medical Oncology16 and National Comprehen-
sive Cancer Network) and resulted in approval for pemetrexed
in the first-line NSCLC setting for patients with nonsquamous
histology. In addition, several regulatory bodies have subse-
quently restricted the approval for second-line use of pem-
etrexed in NSCLC to nonsquamous patients. It seems that
making the distinction between nonsquamous NSCLC and
squamous cell carcinoma is important not only for “tailoring”
drug therapy for efficacy but also for patient safety. For
example, the Food and Drug Administration has approved
bevacizumab for use only in nonsquamous NSCLC as it is
associated with a high risk of bleeding in patients with
squamous cell carcinoma.17,18
Given this apparent treatment-by-histology interaction
effect in newer NSCLC therapies, the differentiation between
squamous and nonsquamous NSCLC at diagnosis has now
gained new importance for guiding patient management and
choice of therapy. The ability to make this distinction has
been particularly pertinent for international reimbursement
agencies considering funding for agents with additional ben-
efit in patients with nonsquamous NSCLC. Several studies on
the diagnostic agreement in the histopathologic evaluation of
lung cancer tissue have been performed in the past,19–26 but
none have specifically addressed the differentiation between
squamous versus nonsquamous NSCLC that has now become
pertinent to clinical management.
This systematic review was undertaken to examine the
interobserver consistency of histology in differentiating be-
tween subtypes of NSCLC. Although there are other emerg-
ing techniques to identify tumor subtypes (i.e., genetic testing
and immunohistochemistry), the current review was limited
to the consideration of morphology. Specifically, the research
question was among patients with a diagnosis of NSCLC,
what is the interobserver variability for histology in differen-
tiating between nonsquamous and squamous NSCLC?
MATERIALS AND METHODS
The primary outcome was histology reporting agree-
ment in NSCLC. We undertook a literature search on May 27,
2009, to identify studies that evaluated the reproducibility of
histologic diagnosis by pathologists in the reporting of
NSCLC subtypes. The Embase.com database (comprising
EMBASE and MEDLINE) was searched using a combination
of study search terms (e.g., diagnosis, yield, and agreement),
diagnostic search terms (e.g., accuracy, reliability, sensitivity,
specificity, positive predictive value [PPV], and negative
predictive value [NPV]), disease search terms (non-small cell
lung cancer), and histologic search terms (e.g., histology,
histopathology, and cytology) (literature search details are
available as supplementary material).
All citations identified through the literature search
were screened for eligibility, defined as original articles, in
English language, evaluating histology reporting agreement
in NSCLC. Initially, this was performed using the publication
title and, where available, the abstract. Studies were excluded
if they were not an original study (i.e., review, case study,
conference abstracts, news, and opinion piece), not a study of
patients with lung cancer, or addressed the wrong research
question (i.e., not a study investigating the diagnostic perfor-
mance or reproducibility of histology for the detection of
NSCLC histologic subtypes). The reference lists of eligible
articles were manually searched for additional relevant stud-
ies. Data from eligible publications were extracted into a
standardized data extraction form by one reviewer. The study
design of each eligible article was assessed using the National
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Health and Medical Research Council diagnostic levels of
evidence together with broad bias considerations using the
Quality Assessment of Diagnostic Accuracy Studies tool.27,28
To calculate agreement and diagnostic performance for
detecting nonsquamous from squamous cell carcinoma,
methodology used by Field et al.21 was adopted whereby an
“index test” and “reference test” were allocated to one of the
pathologists/pathology centers in each study. Only those
studies in which more than one pathologist (e.g., a review
panel) reexamined the specimen have been included in the
meta-analysis, with those pathologists diagnoses assigned as
the “true” diagnoses. This facilitated the creation of 2  2
tables with nonsquamous and squamous NSCLC agreement
tabulated. To qualify as a case of NSCLC, both of the patholo-
gists/pathology centers had to classify the histology sample as
NSCLC (i.e., squamous, adenocarcinoma, large cell, or mixed).
Within the eligible studies, there were no tumors classified as
“NSCLC-not otherwise specified (NOS).” If one pathologist/
pathology center classified the sample as NSCLC but the other
classified the sample as SCLC or not lung cancer, the case was
excluded. The proportion of excluded samples has been reported
in the results.
For eligible studies, where applicable, four separate sets
of results are presented. Initially, the results as they are presented
in the publications are summarized. This includes a summary of
the interobserver agreement and associated kappa statistic () for
the entire population (i.e., including those with SCLC or another
tumor type). The analysis titled “NSCLC exact subtype agree-
ment” involved the calculation of overall agreement and the 
for individual subtypes of NSCLC (i.e., excluding those with
SCLC or another tumor type).
Reanalyses of data were also undertaken to permit
comparison of agreement in nonsquamous and squamous cell
carcinoma (i.e., to determine potential misclassification be-
tween nonsquamous and squamous subtypes of NSCLC), as
this is the research question relevant to this review. Reanal-
ysis 1 examined the exact agreement between nonsquamous
(adenocarcinoma, large cell, or mixed) and squamous NSCLC,
and reanalysis 2 examined the exact agreement between
nonsquamous (adenocarcinoma and large cell) and squamous
(squamous and mixed) NSCLC based on 2 2 tables (Figure
1). The reason for reanalysis 2 was that in the context of
reimbursement listings for therapies of NSCLC, it is impor-
tant to understand how misclassifying mixed tumor types as
“squamous cell carcinoma” will affect the treatment choice
(i.e., possible inappropriate treatment choice, with implica-
tions for costs and outcomes). Tumor types such as SCLC
and tumors of a different primary origin are not pertinent to
the question of whether pathologists can differentiate be-
tween NSCLC of nonsquamous and squamous histology.
Meta-analyses were conducted using Review Manager
Version 5.0 and cross-checked using Meta-disc Version 1.4.
Pooled diagnostic performance measures, including sensitiv-
ity, specificity, PPV, and NPV, were calculated as supportive
analyses for reanalysis 1 and reanalysis 2 (Figure 1). The
sensitivity and PPV are the most relevant diagnostic perfor-
mance measures for this research question because they
identify the probability of correctly identifying nonsquamous
histology among patients with NSCLC. In particular, the PPV
is in line with the perspective of the clinician with a present-
ing patient for whom they are considering prescribing che-
motherapy. The PPV is calculated as the number of true
positives, divided by the number of true positives plus false
positives. For example, a false positive constitutes a result in
which the index pathologist diagnosis is nonsquamous, but
the reference pathologist diagnosis is squamous.
In addition, the prevalence of disease (i.e., the propor-
tion of patients with nonsquamous NSCLC) in each study
cohort has been presented. This is an important consideration
because PPV is known to be affected by prevalence, and PPV
results from a cohort with particular prevalence are not
necessarily generalizable to a cohort with a different preva-
lence. The primary meta-analysis examined PPV where the
classification of NSCLC is divided into nonsquamous histol-
ogy (adenocarcinoma, large cell carcinoma, and mixed cell
types) and squamous histology. Several of the articles in-
cluded a category for mixed tumor types (e.g., adenosqua-
mous). These mixed tumor types have been treated in two
NSCLC SCLC OTHER
Adenocarcinoma Large cell
Mixed (eg 
adenosquamous)
NSCLC 
N.O.S Squamous SCLC
Carcinoma of 
different primary 
origin
Re-analysis 
1
Adenocarcinoma Large cell
Mixed (eg 
adenosquamous)
NSCLC 
N.O.S Squamous
Non-squamous Squamous
Re-analysis 
2
Adenocarcinoma Large cell
Mixed (eg 
adenosquamous)
NSCLC 
N.O.S Squamous
Non-squamous Squamous
FIGURE 1. Diagrammatic representation of the analyses presented. NSCLC-NOS, non-small cell lung cancer-not otherwise
specified; SCLC, small cell lung cancer.
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different ways (i.e., grouped with nonsquamous and then
grouped with squamous). Given the debate surrounding the
classification of adenosquamous tumors, we realize that this
is an area of uncertainty.
The second meta-analysis (reanalysis 2) examined PPV
where the classification of nonsquamous histology does not
include mixed cell types. In this instance, nonsquamous cell
carcinoma is defined as adenocarcinoma and large cell car-
cinoma, and squamous cell carcinoma is defined as squamous
cell carcinoma and mixed tumor type. Small cell carcinomas,
other cancers, and categories such as “no carcinoma identi-
fied” were excluded from the meta-analyses as they were not
considered relevant to the argument of whether the nonsqua-
mous subtypes of NSCLC can be differentiated from the
squamous subtype of NSCLC. These data relate to the ques-
tion of being able to reliably diagnose cancer per se or
NSCLC from SCLC.
RESULTS
All 1480 articles identified through the literature search
were screened for eligibility. Five publications from the
primary EMBASE and Medline database search evaluating
the reproducibility of the histology subtype results in NSCLC
were eligible for inclusion. In addition, a manual search of the
reference lists of eligible studies uncovered one further study
for inclusion. Three further studies29,30,31 that discussed the
accuracy of histology diagnosis in NSCLC were found sub-
sequent to the original literature search. Unfortunately, they
did not provide enough information for inclusion in the
agreement reanalysis but are described in the discussion.
Three studies, which initially seemed eligible, were subse-
quently excluded because they reevaluated histology samples
using different tumor classification criteria. These studies
evaluated changes in the relative frequency of the various
histologic types in the same series of cases when using
different WHO tumor classifications. The characteristics of
the six eligible studies are presented in Table 1. It is impor-
tant to note that the study by Yamamoto et al.32 included two
separate analyses, one of surgical and one of nonsurgical
histology specimens.
Most of the eligible studies involved a comparison of
diagnosis from an earlier population-based study or registry
with a subsequent expert review, or agreement between two
pathologists reviewing the same slides. In all studies, the
reviewing pathologist was blinded to the original or alternate
diagnosis, and diagnoses were made based on single repre-
sentative slides, as opposed to a review of the entire case.
Any analyses that included changes in the relative frequency
of the various histologic types in the same series of cases,
because of changes in the tumor classification criteria, were
excluded. All included studies diagnosed cases by hematox-
ylin and eosin, with three studies21,34,35 allowing additional
mucin stains on request. Tumors were classified using the
1981 or 1982 WHO histologic typing of lung tumors9,36
except in the study by Campobasso et al.,35 where the 1967
criteria were used. There were also some NSCLC classified
as “mixed” because they contain components of both squa-
mous and nonsquamous histology.
When reanalyzing the results, only those samples that
were classified as NSCLC by both of the pathologists/pathology
centers were included. The proportion of samples excluded
because they were classified as “SCLC,” “other carcinoma
type,” or “no carcinoma identified” by the pathologist/pathology
center assigned as the “index test” after being classified as
NSCLC by the “reference pathologist/pathology center” is pre-
sented in Table 3. The proportion of excluded histologic samples
ranged from 0.6 to 12.0%.
The prevalence of nonsquamous NSCLC, overall his-
topathological agreement, and kappa from each publication is
presented in Table 2. In addition, three additional analyses are
presented: first, the exact agreement between all individual
subtypes of NSCLC; second, the agreement between nonsqua-
mous and squamous NSCLC with mixed tumor types grouped
with nonsquamous (reanalysis 1); and third, the agreement
between nonsquamous and squamous NSCLC with mixed
tumor types included and treated as squamous NSCLC (re-
analysis 2). The agreement rate in the publications with all
subtypes of lung cancer (including SCLC) ranged from 65.0
to 90.7% (  0.43–0.87). The agreement rate for NSCLC
exact subtype agreement ranged from 67.1 to 89.6% ( 
0.42–0.84). Based on reanalysis 1, agreement ranged from
77.0 to 94.2% (  0.48–0.88). Based on reanalysis 2,
agreement ranged from 80.2 to 93.6% (  0.55–0.87).
The pooled sensitivity, specificity, PPV, and NPV for
reanalysis 1 and reanalysis 2 are presented in Table 3. The
PPV calculated from reanalysis 1 and reanalysis 2 in each of
the eligible studies was meta-analyzed, and the results are
shown in Figures 2A, B. The results show that the PPV was
consistently high in each individual study with only a small
amount of variation between studies. This resulted in a very
high PPV of 96.9% (95.4–98.0%) and 90.8% (88.3–92.9%)
for reanalysis 1 and reanalysis 2, respectively, confirming that
nonsquamous and squamous histology can be reliably differ-
entiated by pathologists in patients with NSCLC.
DISCUSSION
This is the first systematic review to examine the
interobserver agreement of morphology in differentiating
between nonsquamous and squamous NSCLC. Individual
studies have examined diagnostic agreement in subtypes of
lung cancer but never specifically addressed whether pathol-
ogists can reproducibly distinguish between squamous and
nonsquamous NSCLC. This distinction has become more
relevant recently with international regulatory bodies such as
the Food and Drug Administration and the European Medi-
cines Agency registering certain chemotherapies for patients
with nonsquamous NSCLC. From a patient management
perspective, it is important for clinicians to be able to identify
whether the subtype of NSCLC is squamous or nonsqua-
mous. This distinction is also becoming increasingly impor-
tant for payers and budget holders.
It is important to note that many of the studies were
undertaken at a time when histologic analyses by subgroup
had no known impact on choice of treatment, and therefore,
histologic subgrouping of NSCLC may not have been a
particular focus of routine histologic investigation.
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Our study findings indicate that there is reasonably high
agreement by pathologists in differentiating the broader def-
initions of nonsquamous and squamous NSCLC. Based on
the primary reanalysis of data, agreement between patholo-
gists in differentiating nonsquamous and squamous histology
ranged from 77.0 to 94.2% (  0.48–0.88). In both meta-
analyses, regardless of whether mixed tumor types were
treated as nonsquamous or squamous NSCLC, the diagnostic
performance of histology was consistently high. All diagnos-
tic performance measures were above 79%, with PPV for
nonsquamous histology being 96.9% in reanalysis 1 and
90.8% in reanalysis 2.
The results of the current systematic review are supported
by the agreement result reported in a recent clinical trial (pub-
lished after the date of the literature search), albeit for a small
subsample of patients. In this study, assessing the use of pem-
etrexed for maintenance therapy in patients with NSCLC, a
small, random, masked, central pathology review was under-
taken for 93 of 663 (14%) of patients who had specimens
submitted for the purpose of a companion biomarker study. A
retrospective analysis of this review determined that there was
89% agreement between the investigator assessment and inde-
pendent review of histologic diagnosis in the differentiation of
nonsquamous and squamous NSCLC tumors.13
TABLE 1. Included Study Characteristics
Author (Year)
Country Study Type (N) Patients
Index Test
(Histological Sample:
Year(s) of Diagnosis/
Review)
Reference Test (Histological
Sample: Year(s) of
Diagnosis/Review)
Same
Slides?a
Classification of
Tumors
Level II diagnostic
evidence
Field et al.
(2004)21 the
United States
Agreement between
population-case-
control study and
independent
pathology review;
N  413
Female patients
with primary
lung cancer,
aged 40–84
yr
Cancer registry
classification: Tissue
slides examined
under light
microscope: 1993–
1997
Independent histology review:
Tissue slides examined
under light microscope. In
some cases, special stains
were requested: year not
specified
No 1981 WHO histological
typing of lung
tumors
Yamamoto et al.
(2000)32
Japan
Reproducibility of
diagnosis—histology
review of cases; N
 799 1979–1980
and N  587 (1987)
Primary lung
cancer
patients in
Osaka,
Japan, 1979–
1980 and
1987
Pathologist 1: Resected,
biopsy, cytology
specimen. Slides
stained with
hematoxylin and
eosin: year not
specified
Pathologist 2: Resected,
biopsy, cytology specimen.
Slides stained with
hematoxylin and eosin:
year not specified
Yes 1981 WHO histological
typing of lung
tumors
Level III-1
diagnostic
evidence
Stang et al.
(2006)33
Germany
Agreement between
population-case-
control study and
independent review;
N  668
Born 1913 or
later, treated
in hospital
1988–1993
Regional pathologist
Histological slides or
formalin-fixed lung
tissue: year not
specified
Central pathologist
Histological slides or
formalin-fixed lung tissue:
year not specified
Yes 1981 WHO histological
typing of lung
tumors
Brownson et al.
(1995)34 the
United States
Review of pathologic
material from a
case-control study;
N  482
Nonsmoking
women, aged
30–84 yr,
1986–1991
Missouri cancer
registry: Tissue slides
examined using a
multihead
microscope: 1986–
1991
Panel review: Tissue slides
examined using a
multihead microscope: year
not specified
Yes 1982 WHO histological
typing of lung
tumors
Campobasso
et al. (1993)35
Italy
Interobserver
reproducibility in
lung cancer typing
from a case series;
N  742
Lung cancer
cases from
Turin
University,
1954–1974
Observer 1: Slides from
resection stained with
hematoxylin and
eosin: year not
specified
Observer 2: Slides from
resection stained with
hematoxylin and eosin:
year not specified
Yes 1967 WHO histological
typing of lung
tumors
Hanai et al.
(1987)24 the
United
Kingdom/
Japan
Histology diagnosis
comparison study;
N  112
Lung cancer
cases from
Manchester,
England, and
Osaka,
Japan, 1971–
1984
Manchester
pathologists: Slides,
stained with
hematoxylin and
eosin, surgical
resection material,
stratified, so that
approximately one
third were squamous,
adenocarcinoma and
other:1982–1984
WHO pathologist: Slides,
stained with hematoxylin
and eosin, surgical
resection material,
stratified, so that
approximately one third
were squamous,
adenocarcinoma and other:
year not specified
Yes 1981 WHO histological
typing of lung
tumors
a Were the exact same slides examined in the “index” and “reference” test.
WHO, World Health Organization.
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In another recent study, available as a conference ab-
stract only, 12 lung pathology experts and 12 community
pathologists scored slides from 96 lung cancers, based on the
44 possible WHO diagnostic categories, totaling 222 pathol-
ogist pairs and 7130 slide pairs. Here, the pathologists rated
the confidence in their diagnosis as high 53%, somewhat
38%, and not confident 8%, with 92% of slides rated as
having sufficient quality. The histologic distribution included
30% squamous cell carcinoma and 36% adenocarcinoma. For
the distinction of squamous versus nonsquamous carcinoma,
the  value for overall agreement among all pathologists was
0.55, whereas for expert pathologists,   0.64 and for
community pathologists,   0.41. The authors concluded
that reproducible diagnosis of squamous cell cancer based
on morphology alone is inadequate. These kappa values
appear at the lower end of the spectrum of agreement
compared with the agreement reported in the included
studies of the current review (reanalysis 1:   0.55–
0.88). It is difficult to ascertain why there might have been
differences in the observed agreement in the study by
Grilley-Olson et al.37 relative to the current review, be-
cause the study is only available in abstract form.
A case-control study of lung carcinoma and radon expo-
sure in German Uranium miners also reported histopathologic
findings.31 To clarify diagnosis, a random proportion (65%) of
histologic slides from which the index pathologist made the
original classification of lung tumor diagnosis was reviewed by
a reference pathologist. The proportion of the cell types diag-
nosed by the clinical pathologist that were confirmed by the
reference pathologist was high (82% for patients who received a
diagnosis of SCLC, 72% for squamous cell carcinoma, and 81%
for adenocarcinoma).
Two studies by Burnett et al.29,30 examined observer
variability in histopathological reporting of NSCLC in bron-
chial biopsy specimens. The first involved 11 histopatholo-
gists reviewing 100 randomly selected bronchial biopsy spec-
imens stained with hematoxylin and eosin. No epithelial
mucin stains were available. The pathologists graded their
responses into two degrees of confidence (grade I, high
confidence and grade II, low confidence) based on the nature
of the biopsy material itself. Individual subtype agreement
rather than nonsquamous and squamous agreement was re-
ported. For grade I confidence, the  value was 0.37 for
squamous, 0.58 for adenocarcinoma, and 0.22 for large cell
undifferentiated tumors. The authors suggested that the poor
agreement is because large cell undifferentiated carcinoma of
the lung represents squamous carcinomas and adenocarcino-
mas whose poor degree of differentiation precludes their
inclusion into a more specific diagnostic category, especially
when limited material is available for study.29
The second study involved 12 histopathologists review-
ing 100 randomly selected bronchial biopsy specimens; how-
ever, for each case, two sections were circulated, one stained
by hematoxylin and eosin and the other by a standard method
for mucin (Alcian blue/periodic acid Schiff). Again, each
reviewer gave an indication of their level of confidence with
their diagnosis. Where pathologists were confident in their
classification, both squamous carcinoma (  0.73) andTA
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adenocarcinoma (  0.83) were well recognized, whereas
large cell carcinoma agreement was moderate (  0.51).
Overall, for grade I confidence, pathologists were good at
subclassifying the NSCLC sections ( 0.71). Nevertheless,
for all samples, the results were only fair ( 0.39). The
authors concluded that with adequate bronchial biopsy mate-
rial, NSCLC can be correctly subcategorized.30
When using histology, optimal tissue collection is im-
portant for a precise classification of subtypes of lung tu-
mors.8 There are four commonly used methods of obtaining
tissue samples: sputum cytology; bronchoscopy with wash-
ings, brushings, and biopsies; transthoracic or transbronchial
needle aspiration biopsy or core biopsy; and excisional
biopsy.8,38 Light microscopy is still the leading criterion for
pathologic diagnosis and therapy planning of lung cancer
and, therefore, the most broadly accessible method for “tai-
loring” treatment available today.8,39 Tumor differentiation
using histology can sometimes be restricted by the morpho-
logic heterogeneity of tumors, with variation in appearance
and differentiation from microscopic field to field and from
one histologic section to the next.8,39 Despite the heteroge-
neity of tumors, however, the results of this study suggest that
there is good interobserver agreement by pathologists in
distinguishing between nonsquamous and squamous subtypes
of NSCLC.
If a specific diagnosis cannot be made based solely
on morphology, ancillary techniques including histochem-
istry, immunohistochemistry, electron microscopy, and
molecular biologic methods may prove useful in further
subclassifying NSCLC and can increase the reliability of
the histopathologic evaluation.3,33 A recent study con-
cluded that immunohistochemistry is a useful tool to refine
the subtyping of NSCLC in bronchoscopically derived
biopsy samples in those cases where discrimination be-
yond a generic diagnosis of NSCLC-NOS is not possible.40
The study found the true NSCLC subtype of undifferenti-
ated NSCLC samples was best predicted using Alcian
blue/periodic acid Schiff plus p63 and thyroid transcrip-
tion factor 1 immunohistochemistry, allowing specific sub-
typing in 73% of NSCLC-NOS cases with 86% accuracy.40
Adenocarcinoma is often positive for thyroid transcription
factor-1 and cytokeratin 7 but negative for cytokeratin 5/6,
p63, and 34BE12. Squamous cell carcinoma usually demon-
strates the reverse immunophenotypic features.3
There are several factors that limit our findings. First,
the research question was limited to interobserver agreement
and misclassification between nonsquamous and squamous
NSCLC histology, rather than between nonsquamous and
squamous histology among all lung cancers. Nevertheless,
only a small percentage (0.6–12%) of histology samples was
FIGURE 2. A, Reanalysis 1. PPV:
nonsquamous (adenocarcinoma,
large cell carcinoma, or mixed) ver-
sus squamous (squamous). B, Re-
analysis 2. PPV: nonsquamous (ade-
nocarcinoma and large cell
carcinoma) versus squamous (squa-
mous cell carcinoma and mixed).
PPV, positive predictive value; CI,
confidence interval; df, degrees of
freedom.
TABLE 3. Pooled Diagnostic Performance Measures for Reanalysis 1 and Reanalysis 2
Analysis Sensitivity (%) Specificity (%) PPV (%) NPV (%)
1. Nonsquamous (adenocarcinoma, large cell, and mixed)
vs. squamous
92.3 (90.2–94.0) 90.3 (85.9–93.7) 96.9 (95.4–98.0) 78.2 (73.0–82.9)
2. Nonsquamous (adenocarcinoma and large cell) vs.
squamous (squamous and mixed)
88.7 (86.0–90.9) 83.5 (79.3–87.1) 90.8 (88.3–92.9) 80.0 (75.7–83.9)
NPV, negative predictive value; PPV, positive predictive value.
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classified as nonsquamous or squamous by one pathologist
and as SCLC or nonlung carcinoma by the other pathologist.
Nevertheless, from a clinical management perspective, whether
the initial diagnosis of cancer and nonsquamous NSCLC is
reliable is a question that is broader than the current review but
still highly relevant.
The arbitrary definition of one of the pathologists/
pathology centers as a “reference standard” and the other one
as the “index test” should be considered when interpreting the
diagnostic performance results. Only those studies in which
more than one pathologist (e.g., a review panel) reexamined
the specimen have been included in the meta-analysis, with
those pathologists diagnoses assigned as the “true” diagnoses.
This was a necessary step to calculate the diagnostic perfor-
mance measures, but one should be cognizant of it. It is well
known that PPV is influenced by the prevalence of disease or
“disease positives” within a given cohort. In this case, prev-
alence refers to the proportion of patients with the character-
istic of interest—nonsquamous histology. In our systematic
review, the eligible studies were highly representative of the
likely proportion of patients diagnosed with nonsquamous
NSCLC in clinical practice. The percentage of NSCLC of
nonsquamous histology in the eligible studies, reported as a
weighted average, is comparable with the percentage of
nonsquamous NSCLC found in a recent, large randomized
controlled trial (67.6% versus 72.6%, respectively).11
As this study was a review and meta-analysis of pub-
lished, peer-reviewed articles, there were aspects of the eli-
gible studies methodologies that were ambiguous in the
published texts and limited the interpretation of results. For
example, although the publications generally described the
methods by which the material was examined, it is unclear in
the study by Field et al.21 whether the pathologist/pathology
centers viewed the exact same histologic material in all
studies. Nevertheless, if they did not review the same slides,
this would probably lead to an underestimation of agreement
between the reviewers. In addition, we could not examine the
influence of the source (lavage, biopsy, or lung resection),
amount of specimen and tissue, type of lung cancer material
(cytology, histology), and use of additional staining tech-
niques, which are all thought to have an influence on the
agreement rate.
There also seemed to be one included study with case
selection bias. Yamamoto et al.32 excluded 49 cases out of
a possible 1435 because of inadequate quality of histology
or cytology specimen. This is likely to improve the agree-
ment result.
Finally, the eligible studies for our systematic review
all used either the 1967 or the 1981 or 1982 edition of the
WHO lung tumor classification. Since then, the third (1999)41
and fourth editions (2004)8 have been published by the WHO.
The broad definitions for squamous and nonsquamous carci-
noma have not changed significantly in that time, but more
subtypes have been identified. Given that new emphasis is
now placed on the distinction between squamous and
nonsquamous histologies, it remains to be seen whether there
will be a “diagnostic drift” attributable to pathologists clas-
sifying tumors with more subtle features into one or other of
these categories. Furthermore, it is uncertain whether this
further classification of tumors with subtle features will hold
the same predictive significance.
CONCLUSION
The results of this systematic review and meta-analysis
suggest that pathologists can reliably classify the great ma-
jority of NSCLC into the broad groups of nonsquamous and
squamous NSCLC. Nevertheless, as has been previously
reported, there seems only moderate agreement in the classi-
fication of individual subtypes of NSCLC. The distinction
between nonsquamous and squamous NSCLC is now clini-
cally important in guiding oncologists’ decision making in
choosing the most appropriate therapy for their patients.
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